Legal Opinion
Abraxis Bioscience, Inc. v. NAVINTA, LLC
District Court, D. New Jersey
Decided August 3, 2009No. Civil Action 07-1251 (JAP)PublishedCited by 6 opinions
1Opinion of the Court
OPINION
PISANO, District Judge.
This patent infringement action arises out of the filing of an Abbreviated New Drug Application (“ANDA”) by Navinta, LLC (“Navinta”), a generic drug manufacturer, to market a generic version of an injectable form of the anesthetic Naropin. Naropin is indicated for the production of local or regional anesthesia for surgery and for acute pain management. Plaintiffs, Abraxis Bioscience, Inc. (“Abraxis”) and APP Pharmaceuticals, LLC (collectively, “APP Pharma”), 1 bring this action alleging that Defendant’s filing of the ANDA constituted infringement of three patents…
2Cases cited39 opinions
- MARKMAN Et Al. v. WESTVIEW INSTRUMENTS, INC., Et Al.Supreme Court of the United States · 1996
- Edward H. Phillips v. Awh Corporation, Hopeman Brothers, Inc., and Lofton Corporation, Defendants-CrossCourt of Appeals for the Federal Circuit · 2006
- Herbert Markman and Positek, Inc. v. Westview Instruments, Inc. And Althon Enterprises, Inc.Court of Appeals for the Federal Circuit · 1995
- Vitronics Corporation v. Conceptronic, Inc.Court of Appeals for the Federal Circuit · 1996
- Sony Corp. of America v. Universal City Studios, Inc.Supreme Court of the United States · 1984
34 more not listed; retrieve them via the Exa API.
3Cited by6 opinions
- Abraxis Bioscience, Inc. v. NAVINTA LLCCourt of Appeals for the Federal Circuit · 2010
- Aventis Pharma S.A. v. Hospira, Inc.District Court, D. Delaware · 2010
- Orexigen Therapeutics, Inc. v. Actavis Labs. FL, Inc.District Court, D. Delaware · 2017
- Eli Lilly and Co. v. Actavis Elizabeth LLCDistrict Court, D. New Jersey · 2009
- Novartis Pharmaceuticals Corp. v. Breckenridge Pharmaceutical, Inc.District Court, D. Delaware · 2017
1 more not listed; retrieve them via the Exa API.